[A retrospective survey on practice of oral anticoagulant therapy in patients with cardiovascular diseases].
BACKGROUND
Recently there are several evidence based facts about the beneficial effect of oral anticoagulant therapy in patients with cardiovascular diseases. In the other hand the often serious bleeding complications as well as the ineffective antithrombotic therapy should be avoided.


OBJECTIVE
Authors had examined with a questionnaire some characteristic parameters of oral anticoagulant therapy in Hungarian hospitals. Based on the results they carried out a retrospective survey (488 consecutive patients) on the accuracy and other peculiarity of long-term acenocoumarol therapy in the district of County Hospital Gyula.


CONCLUSIONS
Mean value of all coagulation test's results (INR: 2.72 +/- 1.07, prothrombin %: 36.11 +/- 10.52) suggest a relatively favourable therapeutic activity in the patients required acenocoumarol therapy. According to their data the proportion of newly introduced anticoagulant therapy secondary to atrial fibrillation was highly increased (42%). They stated that the accuracy of documentation in conducting of oral anticoagulant therapy should be improved and it would be the time to use obligatory the INR value in the clinical practice. They found the best therapeutic punctuality among the patients controlled in the Special Cardiological Outpatient Department. There were relatively few event of serious bleedings. The authors called attention to the patients (about 5%) who were treated without any special cause for a longer period of time than it was necessary. They emphasize the pivotal role of permanent education of patients and the importance of their therapeutic compliance in the appropriate oral anticoagulant control.
Katona
András
A
Békés megyei Képviselotestület Pándy Kálmán Kórháza, II. Belgyógyászati Osztály, Kardiológia, Gyula.
Márk
László
L
D000074:Acenocoumarol / Q000008:administration & dosage* / Q000009:adverse effects; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D006814:Hungary; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D010349:Patient Compliance; D010353:Patient Education as Topic; D011516:Prothrombin / Q000378:metabolism; D011787:Quality of Health Care; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D000925:Anticoagulants; D011516:Prothrombin; D000074:Acenocoumarol
Az orális antikoaguláns kezelés gyakorlatának retrospektív elemzése kardiovaszkuláris betegségben szenvedo betegekben.